Simulations Plus (NASDAQ:SLP) Trading Down 4.2% – What’s Next?

Shares of Simulations Plus, Inc. (NASDAQ:SLP) dropped 4.2% during mid-day trading on Tuesday . The stock traded as low as $33.01 and last traded at $32.74. Approximately 53,890 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 188,230 shares. The stock had previously closed at $34.16.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, January 8th. StockNews.com downgraded Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday. Finally, KeyCorp increased their target price on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $49.40.

Simulations Plus Stock Performance

The company’s 50-day moving average price is $28.84 and its two-hundred day moving average price is $30.04. The stock has a market cap of $654.21 million, a PE ratio of 81.33 and a beta of 1.13.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Thursday, April 3rd. The technology company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. The business had revenue of $22.43 million for the quarter, compared to analysts’ expectations of $21.93 million. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The business’s quarterly revenue was up 22.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.20 EPS. Equities research analysts forecast that Simulations Plus, Inc. will post 1.09 earnings per share for the current fiscal year.

Insider Activity at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the sale, the director now owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. This trade represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 19.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Barclays PLC grew its stake in Simulations Plus by 390.6% during the third quarter. Barclays PLC now owns 28,473 shares of the technology company’s stock valued at $911,000 after acquiring an additional 22,669 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Simulations Plus during the fourth quarter valued at $719,000. Geode Capital Management LLC grew its position in shares of Simulations Plus by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock worth $14,367,000 after buying an additional 18,924 shares in the last quarter. State Street Corp raised its stake in Simulations Plus by 4.7% in the third quarter. State Street Corp now owns 640,303 shares of the technology company’s stock worth $20,503,000 after buying an additional 28,953 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Simulations Plus by 106.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company’s stock worth $1,517,000 after buying an additional 24,371 shares during the last quarter. 78.08% of the stock is currently owned by institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.